Latest Coronado Biosciences (CNDO) Headlines Is A

New Post Public Reply Private Reply Replies (0) Message Board

Mar 9, 2014 at 10:27 AM

Latest Coronado Biosciences (CNDO) Headlines

Is A Short Squeeze Ahead for Coronado Biosciences (CNDO)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 9:24AM CST
Is A Short Squeeze Ahead for Coronado Biosciences (CNDO)?

Arkansas Leading Change in College Student Experience
Marketwire - Tue Feb 25, 6:04AM CST
Today, Achieving the Dream released Continuous Improvement for College Completion: Arkansas Builds a System-Level Strategy for Community College Student Success during a session at DREAM 2014. This report details the coordinated efforts of Arkansas that has significantly improved the progress of student outcomes at two-year colleges across the state.

5 Biotech Stocks to Trade for Breakouts
at The Street - Mon Feb 24, 1:08PM CST
Here's a technical look at five potentially explosive biotech stock plays.

Qiagen to Simplify Next-Generation Sequencing - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 5:00PM CST
Qiagen recently divulged its plans to launch innovative products.

Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (strong buy) List for Thursday

Coronado Shares Continue to Soar on Patent Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 4:00PM CST
The USPTO has granted a second key patent for Coronado's CNDO-109.

Coronado Biosciences Granted a Second Key Patent for CNDO-109, an Activator of Natural Killer Cells
GlobeNewswire - Thu Feb 06, 7:00AM CST
Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company involved in the development of novel immunotherapy agents for the treatment of autoimmune diseases and cancer, as well as the licensing and acquisition of, and investment in, development stage compounds, biologics and companies, today announced the U.S. Patent and Trademark Office (USPTO) has granted a second key patent for CNDO-109 directed to the activated Natural Killer (NK) cell compositions employed in its NK cell therapy program, and has further issued a Notice of Allowance in an additional pending application directed to pharmaceutical compositions comprising these activated NK cells. The activated NK cells are prepared by a patented process licensed by Coronado from UCL Business PLC, which is already the subject of a previously-granted U.S. patent. Similar patent protection has been obtained in Australia and India and applications are still pending in Europe, Japan and Canada.

Synthetic Biologics (SYN) Slumps: Stock Tanks 11.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 28, 7:38AM CST
Synthetic Biologics shares fell by over 11%. This recent price action is discouraging, so make sure to keep a close watch of this firm in the near future.

Why XOMA Corporation (XOMA) Has A Bright Short-Term Future? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 24, 7:40AM CST
XOMA Corporation has seen its Zacks Rank surge over the past four weeks, moving from Sell territory to its current position as a Buy

Coronado Biosciences (CNDO) Jumps: Stock Up 6.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 20, 8:39AM CST
Coronado Biosciences, Inc. was a big mover last session, as its shares rose over 6% on the day.

Why Acceleron (XLRN) Has A Bright Short-Term Future? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 20, 7:30AM CST
Acceleron has seen its Zacks Rank move up from Neutral to Buy over the past four weeks

5 Stocks Ready to Break Out
at The Street - Fri Jan 17, 12:24PM CST
These stocks are poised to break out and trade higher from current levels.

Impax's Outlook for 2014 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 16, 6:15PM CST
Impax provides financial guidelines for the current fiscal year.

Pipeline Update from XenoPort - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 16, 5:50PM CST
XenoPort provides update on its pipeline

Zacks #1 Rank Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 16, 8:30AM CST
Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List for Thursday

AFFX, Bristol University in Array Tie-Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 14, 1:20PM CST
Affymetrix collaborates with the University of Bristol to design wheat genotyping array.

Can the Rally in Coronado Biosciences Inc. (CNDO) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 07, 6:46AM CST
Can the Rally in Coronado Biosciences Inc. (CNDO) Shares Continue?

Synthetic Biologics (SYN) Jumps: Stock Up 5.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 03, 7:51AM CST
Synthetic Biologics Inc. was a big mover last session, as its shares rose over 5% on the day.

Pluristem (PSTI) Jumps: Stock Adds 8.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 02, 7:37AM CST
Pluristem Therapeutics, Inc. was a big mover last session, as the company saw its shares nearly 9% on the day.

Fortress Biotech, Inc. (FBIO) Stock Research Links

FBIO Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Faith and Resilience in China: The Legacy of the Long March

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Antheia Secures $80M for Critical Medicine Onshoring

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

UEG's New Advisory Board: Elevating Patient Voices

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

ASTS Faces a Legal Countdown – Investors Take Note

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Lundbeck's Board Leadership Transitions into New Era

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

AEVEX Faces 48-Hour Deadline for Investor Class Action

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Tomorrowland's Shanghai Return: An Electri-Lifesaver

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...